Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Jérôme Cros — scientific strength (skeptical take): Publication productivity and citation visibility appear strong in parts of immunology/virology/cancer biology based on bibliometric signals, but the provided “author-specific” paper list conflicts with OpenAlex-disambiguation signals, so author identity/record matching is a major uncertainty that must be resolved before over-weighting any single-paper conclusions. [Validate author identity]



     Long Explanation


    Author Review: Jérôme Cros

    Evidence-based, skeptical, with inline citations for every sourced claim.
    What I received (and the key risk):
    • “Author Review: Jérôme Cros” plus (i) a 2-paper list and (ii) an OpenAlex author bundle with different bibliometric signals and top works.
    • Major epistemic risk: bibliometric systems often merge similarly named researchers; your provided data includes multiple candidate author records and also a “papers” list that does not obviously match the OpenAlex top-works pattern. Therefore, identity disambiguation is the first thing that can change the conclusion.
    Source for the OpenAlex bundle and author page used here: https://openalex.org/A5060346666 (from your provided OpenAlex snapshot).
    Visual 1 — OpenAlex “counts_by_year”: productivity vs citations
    Data source: provided OpenAlex snapshot for https://openalex.org/A5060346666. (No DOI exists for the OpenAlex metadata bundle itself.)
    Visual 2 — Bibliometric “focus” by topic (OpenAlex concepts)
    Data source: provided OpenAlex snapshot for the top author record. https://openalex.org/A5060346666.
    Visual 3 — One-step bibliographic landscape: 5 OpenAlex “top works”
    Citation counts/selection: from the provided OpenAlex snapshot. Works themselves cited below.

    Scientific strength: what can be supported from provided evidence

    1) Breadth of biological themes (from OpenAlex top works)

    The OpenAlex “top works” suggest recurring engagement with innate immunity/interferon sensing, viral antagonism, and cancer biology / tumor microenvironment.
    • Innate immune sensing via TLR7/8:
    • Interferon regulatory factor activation and SARS-CoV interferon induction dynamics:
    • Virus-encoded interferon antagonism (NDV V protein; comparison to Nipah V/W/C proteins):
    • Oncology synthesis/therapy framing (review):
    • Tumor stratification combining tumor and microenvironment features (cancer data integration):
    Skeptical note: These are top works and do not prove authorship contribution depth (e.g., first/last author vs. middle author). Also, bibliometric prominence can reflect field popularity and network effects, not necessarily individual scientific rigor.

    Consistency check: the 2-paper list vs. OpenAlex top-works mismatch

    Your input includes exactly two paper titles related to short bowel syndrome and teduglutide / intestinal mitochondrial function / Pappalysin-2 as an efficacy marker. However, the OpenAlex snapshot’s provided “top works” prominently feature immunology/virology and cancer biology. With only titles and no author-order metadata for the two SBS papers in the prompt, the safest conclusion is that either: (a) multiple people named “Cros/Jérôme Cros” are being conflated, or (b) the SBS papers are from a different subset/period not represented in the shown OpenAlex top-works.
    • Because no DOI/venue/year/details were provided for the two SBS papers, I cannot responsibly critique their methods or evidence strength here.
    • Actionable next step: resolve record disambiguation (ORCID, full name variants, affiliations, and DOI set) before making any author-level scientific claims based on bibliometrics.

    What would most strengthen (or weaken) confidence

    Most important disconfirming information

    • For any claim that “Jérôme Cros” is a leading author in a specific subfield, we need ground-truth mapping of all relevant papers to the correct author identity (ORCID / affiliation / full author list).
    • Methodological rigor must be checked directly from full text: experimental controls, sample sizes, replication, blinding, statistical modeling choices, and whether key findings were validated in independent cohorts or orthogonal assays.
    • Bibliometric records can merge/fragment identities: without disambiguation, “h-index/citations” can mislead.

    Potential blind spots in this review (given your provided data)

    • I did not receive the actual SBS paper DOIs, author positions, raw results, or full text—so I cannot evaluate scientific rigor for those specific works.
    • I used OpenAlex-derived bibliometric metadata shown in your prompt; these are not substitute for paper-level critical appraisal.
    • Top-work selection bias: “top works” likely emphasize high-impact items and may miss methodological failures or null results.
    Suggested BGPT follow-up queries (to make this truly rigorous)


    Feedback:    

    Updated: April 18, 2026

     BGPT Author Review


    Scientific Quality

    60%

    Moderately high scientific quality signal from OpenAlex bibliometrics and participation in mechanistic immunology/virology and cancer biology papers, but this review is constrained by the prompt’s likely author-disambiguation ambiguity (multiple “Cros/Jérôme Cros” records) and missing full-text/method-level data for the specific two SBS papers listed. Therefore, credibility is plausible yet not verifiably strong at the individual-paper rigor level.


    Communication Quality

    50%

    Communication quality cannot be directly assessed from the provided data (titles only + bibliometrics). The presence of reviews suggests some ability to synthesize, but no writing artifacts (abstracts/full text) were provided to evaluate clarity, framing, or methodological transparency.


    Author Novelty

    50%

    The provided evidence points to established research themes (innate sensing/IFN biology, TLRs, viral antagonism, tumor microenvironment). Novelty is plausible, but the prompt lacks enough paper-level detail to judge whether contributions were primarily incremental vs. conceptually transformative.


    Scientific Rigor

    60%

    Mechanistic virology/immunology topics often require strong experimental controls, but this cannot be confirmed here. With only bibliometric metadata and no full methods/results for the key claimed works, rigor assessment is necessarily limited and should be treated as provisional.

     Analysis Wizard



    This will fetch the disambiguated author’s DOI list, retrieve full-text-accessible figures/tables, then tabulate assay types, sample sizes, and reported effect sizes across papers to support a reproducibility-focused rigor profile.



     Hypothesis Graveyard


    The SBS teduglutide biomarker claims (Pappalysin-2/mitochondrial function) are definitively causal in all SBS patients—this is unlikely without strong cohort validation and mechanistic causality tests; the current prompt lacks that evidence.


    High OpenAlex citation counts directly measure individual rigor and experimental quality—bibliometrics can be inflated by topic popularity, coauthor networks, and identity conflation, so it’s not sufficient for rigor without full-text appraisal.

     Science Art


    Author Review: Jérôme Cros Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending